Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.


Biotechnology

Pharmaceutical

Therapeutics

Carbon Biosciences

Joel Schneider

Steve Dipalma

Sebastian Aguirre Kozlouski, Ph.D.

Yoshi Hashimoto

Jianming Qiu

Jeff Moffit, PhD, DABT

Beckett Hart

Robert M. Kotin

Marc Abrams

Linda Bruett

Amy Lurier

Sebastian Aguirre

Josh Merritt

Jeff Moffit

Scientific and Research Team

Leadership Team

Development Team

Process Development

Teams at Carbon Biosciences

Scientific and Research Team

Leadership Team

Development Team

Process Development